ACE2 and COVID-19: In contrast, blocking ACE2 in COVID-19 individuals who are already infected could be harmful because it would lead to less angiotensin 1–7 synthesis, which has been shown to have anti-inflammatory and antifibrotic properties through its receptor [5].